SYRE — Spyre Therapeutics Inc.

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Spyre Therapeutics Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$72.11
Market Cap$6.45B
Float80.9M
Shares Outstanding86.8M
Price/Sales (TTM)650.22
vs. Analyst Target+32.0% to analyst PT
Earnings Growth (YoY)-99.70%
Dividend RateNone
Analyst Target Price$95.20 (11 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$80.9M -$1.6M -$79.3M
2021 $18.7M -$65.8M $18.7M -$64.1M
2022 $2.3M -$83.8M $2.3M -$82.8M
2023 $886,000 -$339M -$78,000 -$242M
2024 $886,000 -$208M $886,000 -$208M
2025 N/A -$155M -$172M -$210M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$36.7M
Sep 2025 N/A -$11.2M
Dec 2025 $90.5M -$62.5M
Mar 2026 N/A -$69.0M

Ownership & Float

Insider Ownership5.9%
Institutional Ownership97.5%
Short Float15.1%
% of All Funds Holding2.19%
Number of Funds Holding180

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$65.44Near-term / short-term trend
Weekly40-Week SMA$37.78Medium-term trend
Weekly80-Week SMA$28.26Cyclical trend (business cycle)
Weekly200-Week SMA$22.93Secular trend (multi-year)
Monthly10-Month SMA$39.25Near-term monthly trend
Monthly20-Month SMA$29.90Medium-term monthly trend
Monthly40-Month SMA$24.87Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$51.00 support 1.75x 0 months ago
$42.00 support 1.19x 1 months ago
$31.80 support 1.01x 2 months ago
$16.80 support 2.03x 6 months ago

Historical Earnings Reactions (41 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.89% 0.54% 65.85% 10.07% -12.85%
1 Day 0.00% 0.34% 53.66% 14.28% -12.03%
1 Week 2.72% 1.25% 58.54% 38.23% -22.53%
2 Weeks 4.98% 2.94% 65.85% 119.28% -26.51%
1 Month -0.82% 2.91% 53.66% 74.45% -61.67%

Next earnings: July 24, 2026 (55 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan3.5%40.0%10
Feb2.9%50.0%10
Mar2.2%50.0%10
Apr-1.0%20.0%10
May-5.9%50.0%10
Jun11.9%40.0%10
Jul-0.2%40.0%10
Aug10.9%80.0%10
Sep1.7%60.0%10
Oct10.9%40.0%10
Nov0.5%40.0%10
Dec-1.9%40.0%10

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.19% 49.9% 475
Tuesday -0.08% 44.0% 525
Wednesday -0.17% 50.5% 521
Thursday 0.59% 48.4% 512
Friday 0.41% 48.2% 514

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 97.5%

Insider Transactions — Smart Summary

Total insider ownership: 5.9%

12-Month Insider Activity Summary

Total Filings13
Net Value-$9.6M
Net Shares Change-215,000
% of Float-0.3%
C-Suite Filings12
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
HENDERSON MICHAEL THOMAS -$6.0M 1 N/A
Turtle Cameron Chief Executive Officer -$4.9M 7 N/A
Sloan Sheldon Chief Medical Officer -$3.4M 1 N/A
Burrows Scott L Chief Financial Officer -$710,875 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-04-03 – 2026-04-03 3 3 -$1.2M 3 C-suite
2026-05-01 – 2026-05-08 4 4 -$11.2M 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-08 HENDERSON MICHAEL THOMAS -$6.0M Transaction at $74.40, now -3.1%
2026-05-01 Turtle Cameron Chief Executive Officer -$1.1M Transaction at $71.37, now +1.0%
2026-04-03 Turtle Cameron Chief Executive Officer -$739,912.5 Transaction at $49.33, now +46.2%
2026-03-03 Turtle Cameron Chief Executive Officer -$632,866.5 Transaction at $42.19, now +70.9%
2025-11-05 Turtle Cameron Chief Executive Officer -$1.0M Transaction at $23.33, now +209.1%
2026-02-04 Turtle Cameron Chief Executive Officer -$492,045 Transaction at $32.80, now +119.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Spyre Therapeutics Inc. (SYRE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for SYRE on Trend Edge →